Skip to main content
SpringerLink
Log in
Book cover

A Mastery Approach to Complex Esophageal Diseases pp 1–15Cite as

Non-operative Treatment of Gastroesophageal Reflux Disease

  • Chapter
  • First Online:

  • 621 Accesses

Abstract

Gastrointestinal reflux disease (GERD) is the most prevalent gastrointestinal disorder in the United States with considerable morbidity. It is typically characterized by the classic symptoms of heartburn and regurgitation. The management of GERD includes assessment for alarm features which should prompt further investigation. However, in most cases GERD is a presumptive diagnosis that can be treated empirically with proton pump inhibitor (PPI) therapy without extensive diagnostic evaluation. This chapter will review the non-operative management of GERD, including medical therapy as well as the additional diagnostic for patients at risk for complications of GERD.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   99.00
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Vakil N, van Zanten SV, Kahrilas P, Dent J, Jones R, Global Consensus G. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol. 2006;101(8):1900–20; quiz 43. https://doi.org/10.1111/j.1572-0241.2006.00630.x.

    Article  PubMed  Google Scholar 

  2. Wallin L, Madsen T. 12-hour simultaneous registration of acid reflex and peristaltic activity in the oesophagus. A study in normal subjects. Scand J Gastroenterol. 1979;14(5):561–6.

    Article  CAS  PubMed  Google Scholar 

  3. Diener U, Patti MG, Molena D, Fisichella PM, Way LW. Esophageal dysmotility and gastroesophageal reflux disease. J Gastrointest Surg. 2001;5(3):260–5.

    Article  CAS  PubMed  Google Scholar 

  4. Scarpignato C, Gatta L, Zullo A, Blandizzi C, Group S-A-F, Italian Society of Pharmacology tIAoHG, et al. Effective and safe proton pump inhibitor therapy in acid-related diseases - a position paper addressing benefits and potential harms of acid suppression. BMC Med. 2016;14(1):179. https://doi.org/10.1186/s12916-016-0718-z.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Richter JE, Rubenstein JH. Presentation and epidemiology of gastroesophageal reflux disease. Gastroenterology. 2017. doi:https://doi.org/10.1053/j.gastro.2017.07.045.

    Article  PubMed  Google Scholar 

  6. Vitale GC, Cheadle WG, Patel B, Sadek SA, Michel ME, Cuschieri A. The effect of alcohol on nocturnal gastroesophageal reflux. JAMA. 1987;258(15):2077–9.

    Article  CAS  PubMed  Google Scholar 

  7. Nebel OT, Castell DO. Lower esophageal sphincter pressure changes after food ingestion. Gastroenterology. 1972;63(5):778–83.

    CAS  PubMed  Google Scholar 

  8. Derakhshan MH, Robertson EV, Fletcher J, Jones GR, Lee YY, Wirz AA, et al. Mechanism of association between BMI and dysfunction of the gastro-oesophageal barrier in patients with normal endoscopy. Gut. 2012;61(3):337–43. https://doi.org/10.1136/gutjnl-2011-300633.

    Article  PubMed  Google Scholar 

  9. Barham CP, Gotley DC, Mills A, Alderson D. Precipitating causes of acid reflux episodes in ambulant patients with gastro-oesophageal reflux disease. Gut. 1995;36(4):505–10.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Herregods TV, van Hoeij FB, Oors JM, Bredenoord AJ, Smout AJ. Effect of running on gastroesophageal reflux and reflux mechanisms. Am J Gastroenterol. 2016;111(7):940–6. https://doi.org/10.1038/ajg.2016.122.

    Article  PubMed  Google Scholar 

  11. Gerson LB, Fass R. A systematic review of the definitions, prevalence, and response to treatment of nocturnal gastroesophageal reflux disease. Clin Gastroenterol Hepatol. 2009;7(4):372–8; quiz 67. https://doi.org/10.1016/j.cgh.2008.11.021.

    Article  PubMed  Google Scholar 

  12. Zheng Z, Margolis KL, Liu S, Tinker LF, Ye W. Effects of estrogen with and without progestin and obesity on symptomatic gastroesophageal reflux. Gastroenterology. 2008;135(1):72–81. https://doi.org/10.1053/j.gastro.2008.03.039.

    Article  PubMed  Google Scholar 

  13. Richter JE. Typical and atypical presentations of gastroesophageal reflux disease. The role of esophageal testing in diagnosis and management. Gastroenterol Clin N Am. 1996;25(1):75–102.

    Article  CAS  Google Scholar 

  14. Madanick RD. Extraesophageal presentations of GERD: where is the science? Gastroenterol Clin N Am. 2014;43(1):105–20. https://doi.org/10.1016/j.gtc.2013.11.007.

    Article  Google Scholar 

  15. Moore JM, Vaezi MF. Extraesophageal manifestations of gastroesophageal reflux disease: real or imagined? Curr Opin Gastroenterol. 2010;26(4):389–94. https://doi.org/10.1097/MOG.0b013e32833adc8d.

    Article  PubMed  Google Scholar 

  16. Schneider GT, Vaezi MF, Francis DO. Reflux and voice disorders: have we established causality? Curr Otorhinolaryngol Rep. 2016;4(3):157–67. https://doi.org/10.1007/s40136-016-0121-5.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Francis DO, Slaughter JC, Ates F, Higginbotham T, Stevens KL, Garrett CG, et al. Airway hypersensitivity, reflux, and phonation contribute to chronic cough. Clin Gastroenterol Hepatol. 2016;14(3):378–84. https://doi.org/10.1016/j.cgh.2015.10.009.

    Article  PubMed  Google Scholar 

  18. Hachem C, Shaheen NJ. Diagnosis and management of functional heartburn. Am J Gastroenterol. 2016;111(1):53–61; quiz 2. https://doi.org/10.1038/ajg.2015.376.

    Article  PubMed  Google Scholar 

  19. Wang R-H. From reflux esophagitis to Barrett’s esophagus and esophageal adenocarcinoma. World J Gastroenterol. 2015;21(17):5210–9. https://doi.org/10.3748/wjg.v21.i17.5210.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Siddiqui UD, Banerjee S, Barth B, Chauhan SS, Gottlieb KT, Konda V, et al. Tools for endoscopic stricture dilation. Gastrointest Endosc. 2013;78(3):391–404. https://doi.org/10.1016/j.gie.2013.04.170.

    Article  PubMed  Google Scholar 

  21. Siersema PD, de Wijkerslooth LR. Dilation of refractory benign esophageal strictures. Gastrointest Endosc. 2009;70(5):1000–12. https://doi.org/10.1016/j.gie.2009.07.004.

    Article  PubMed  Google Scholar 

  22. Coleman HG, Xie SH, Lagergren J. The epidemiology of esophageal adenocarcinoma. Gastroenterology. 2017. doi:https://doi.org/10.1053/j.gastro.2017.07.046.

    Article  PubMed  Google Scholar 

  23. Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol. 2013;108(3):308–28; quiz 29. https://doi.org/10.1038/ajg.2012.444.

    Article  PubMed  Google Scholar 

  24. Numans ME, Lau J, de Wit NJ, Bonis PA. Short-term treatment with proton-pump inhibitors as a test for gastroesophageal reflux disease: a meta-analysis of diagnostic test characteristics. Ann Intern Med. 2004;140(7):518–27.

    Article  CAS  PubMed  Google Scholar 

  25. Moayyedi P, Talley NJ, Fennerty MB, Vakil N. Can the clinical history distinguish between organic and functional dyspepsia? JAMA. 2006;295(13):1566–76. https://doi.org/10.1001/jama.295.13.1566.

    Article  CAS  PubMed  Google Scholar 

  26. ASoP C, Muthusamy VR, Lightdale JR, Acosta RD, Chandrasekhara V, Chathadi KV, et al. The role of endoscopy in the management of GERD. Gastrointest Endosc. 2015;81(6):1305–10. https://doi.org/10.1016/j.gie.2015.02.021.

    Article  Google Scholar 

  27. Shaheen NJ, Weinberg DS, Denberg TD, Chou R, Qaseem A, Shekelle P. Upper endoscopy for gastroesophageal reflux disease: best practice advice from the clinical guidelines committee of the American College of Physicians. Ann Intern Med. 2012;157(11):808–16. https://doi.org/10.7326/0003-4819-157-11-201212040-00008.

    Article  PubMed  Google Scholar 

  28. Kahrilas PJ, Shaheen NJ, Vaezi MF, Hiltz SW, Black E, Modlin IM, et al. American Gastroenterological Association Medical Position Statement on the management of gastroesophageal reflux disease. Gastroenterology. 2008;135(4):1383–91, 91.e1-5. https://doi.org/10.1053/j.gastro.2008.08.045.

    Article  PubMed  Google Scholar 

  29. DeVault KR, Castell DO, American College of G. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol. 2005;100(1):190–200. https://doi.org/10.1111/j.1572-0241.2005.41217.x.

    Article  PubMed  Google Scholar 

  30. Shaheen NJ, Falk GW, Iyer PG, Gerson LB, American College of G. ACG clinical guideline: diagnosis and management of Barrett's esophagus. Am J Gastroenterol. 2016;111(1):30–50; quiz 1. https://doi.org/10.1038/ajg.2015.322.

    Article  CAS  PubMed  Google Scholar 

  31. Hanna S, Rastogi A, Weston AP, Totta F, Schmitz R, Mathur S, et al. Detection of Barrett's esophagus after endoscopic healing of erosive esophagitis. Am J Gastroenterol. 2006;101(7):1416–20. https://doi.org/10.1111/j.1572-0241.2006.00631.x.

    Article  PubMed  Google Scholar 

  32. Roman S, Gyawali CP, Savarino E, Yadlapati R, Zerbib F, Wu J, et al. Ambulatory reflux monitoring for diagnosis of gastro-esophageal reflux disease: update of the Porto consensus and recommendations from an international consensus group. Neurogastroenterol Motil. 2017;29(10):1–15. https://doi.org/10.1111/nmo.13067.

    Article  CAS  PubMed  Google Scholar 

  33. Vaezi MF, Choksi Y. Mucosal impedance: a new way to diagnose reflux disease and how it could change your practice. Am J Gastroenterol. 2017;112(1):4–7. https://doi.org/10.1038/ajg.2016.513.

    Article  PubMed  Google Scholar 

  34. Ward MA, Dunst CM, Teitelbaum EN, Halpin VJ, Reavis KM, Swanstrom LL, et al. Impedance-pH monitoring on medications does not reliably confirm the presence of gastroesophageal reflux disease in patients referred for antireflux surgery. Surg Endosc. 2018;32(2):889–94. https://doi.org/10.1007/s00464-017-5759-7.

    Article  PubMed  Google Scholar 

  35. Hirano I, Zhang Q, Pandolfino JE, Kahrilas PJ. Four-day bravo pH capsule monitoring with and without proton pump inhibitor therapy. Clin Gastroenterol Hepatol. 2005;3(11):1083–8.

    Article  PubMed  Google Scholar 

  36. Ates F, Yuksel ES, Higginbotham T, Slaughter JC, Mabary J, Kavitt RT, et al. Mucosal impedance discriminates GERD from non-GERD conditions. Gastroenterology. 2015;148(2):334–43. https://doi.org/10.1053/j.gastro.2014.10.010.

    Article  PubMed  Google Scholar 

  37. Ness-Jensen E, Hveem K, El-Serag H, Lagergren J. Lifestyle intervention in gastroesophageal reflux disease. Clin Gastroenterol Hepatol. 2016;14(2):175–82 e1-3. https://doi.org/10.1016/j.cgh.2015.04.176.

    Article  PubMed  Google Scholar 

  38. Phupong V, Hanprasertpong T. Interventions for heartburn in pregnancy. Cochrane Database Syst Rev. 2015;19(9):CD011379. https://doi.org/10.1002/14651858.CD011379.pub2.

    Article  Google Scholar 

  39. De Ruigh A, Roman S, Chen J, Pandolfino JE, Kahrilas PJ. Gaviscon double action liquid (antacid & alginate) is more effective than antacid in controlling post-prandial oesophageal acid exposure in GERD patients: a double-blind crossover study. Aliment Pharmacol Ther. 2014;40(5):531–7. https://doi.org/10.1111/apt.12857.

    Article  PubMed  PubMed Central  Google Scholar 

  40. Leiman DA, Riff BP, Morgan S, Metz DC, Falk GW, French B, et al. Alginate therapy is effective treatment for GERD symptoms: a systematic review and meta-analysis. Dis Esophagus. 2017;30(5):1–9. https://doi.org/10.1093/dote/dow020.

    Article  PubMed  PubMed Central  Google Scholar 

  41. Wolfe MM, Sachs G. Acid suppression: optimizing therapy for gastroduodenal ulcer healing, gastroesophageal reflux disease, and stress-related erosive syndrome. Gastroenterology. 2000;118(2):S9–S31. https://doi.org/10.1016/S0016-5085(00)70004-7.

    Article  CAS  PubMed  Google Scholar 

  42. Mainie I, Tutuian R, Castell DO. Addition of a H2 receptor antagonist to PPI improves acid control and decreases nocturnal acid breakthrough. J Clin Gastroenterol. 2008;42(6):676–9. https://doi.org/10.1097/MCG.0b013e31814a4e5c.

    Article  CAS  PubMed  Google Scholar 

  43. Komazawa Y, Adachi K, Mihara T, Ono M, Kawamura A, Fujishiro H, et al. Tolerance to famotidine and ranitidine treatment after 14 days of administration in healthy subjects without helicobacter pylori infection. J Gastroenterol Hepatol. 2003;18(6):678–82.

    Article  CAS  PubMed  Google Scholar 

  44. Fackler WK, Ours TM, Vaezi MF, Richter JE. Long-term effect of H2RA therapy on nocturnal gastric acid breakthrough. Gastroenterology. 2002;122(3):625–32.

    Article  CAS  PubMed  Google Scholar 

  45. Kahrilas PJ. Gastroesophageal reflux disease. JAMA. 1996;276(12):983–8. https://doi.org/10.1001/jama.1996.03540120061035.

    Article  CAS  PubMed  Google Scholar 

  46. Xue S, Katz PO, Banerjee P, Tutuian R, Castell DO. Bedtime H2 blockers improve nocturnal gastric acid control in GERD patients on proton pump inhibitors. Aliment Pharmacol Ther. 2001;15(9):1351–6.

    Article  CAS  PubMed  Google Scholar 

  47. Ours TM, Fackler WK, Richter JE, Vaezi MF. Nocturnal acid breakthrough: clinical significance and correlation with esophageal acid exposure. Am J Gastroenterol. 2003;98(3):545–50.

    Article  PubMed  Google Scholar 

  48. Hatlebakk JG, Katz PO, Camacho-Lobato L, Castell DO. Proton pump inhibitors: better acid suppression when taken before a meal than without a meal. Aliment Pharmacol Ther. 2000;14(10):1267–72.

    Article  CAS  PubMed  Google Scholar 

  49. Lee RD, Vakily M, Mulford D, Wu J, Atkinson SN. Clinical trial: the effect and timing of food on the pharmacokinetics and pharmacodynamics of dexlansoprazole MR, a novel dual delayed release formulation of a proton pump inhibitor--evidence for dosing flexibility. Aliment Pharmacol Ther. 2009;29(8):824–33. https://doi.org/10.1111/j.1365-2036.2009.03979.x.

    Article  CAS  PubMed  Google Scholar 

  50. Chowers Y, Atarot T, Pratha VS, Fass R. The effect of once daily omeprazole and succinic acid (VECAM) vs once daily omeprazole on 24-h intragastric pH. Neurogastroenterol Motil. 2012;24(5):426–31, e208-9. https://doi.org/10.1111/j.1365-2982.2012.01884.x.

    Article  CAS  PubMed  Google Scholar 

  51. Chiba N, De Gara CJ, Wilkinson JM, Hunt RH. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology. 1997;112(6):1798–810.

    Article  CAS  PubMed  Google Scholar 

  52. Sigterman KE, van Pinxteren B, Bonis PA, Lau J, Numans ME. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database Syst Rev. 2013;31(5):CD002095. https://doi.org/10.1002/14651858.CD002095.pub5.

    Article  Google Scholar 

  53. Kirchheiner J, Glatt S, Fuhr U, Klotz U, Meineke I, Seufferlein T, et al. Relative potency of proton-pump inhibitors-comparison of effects on intragastric pH. Eur J Clin Pharmacol. 2009;65(1):19–31. https://doi.org/10.1007/s00228-008-0576-5.

    Article  CAS  PubMed  Google Scholar 

  54. Gralnek IM, Dulai GS, Fennerty MB, Spiegel BM. Esomeprazole versus other proton pump inhibitors in erosive esophagitis: a meta-analysis of randomized clinical trials. Clin Gastroenterol Hepatol. 2006;4(12):1452–8. https://doi.org/10.1016/j.cgh.2006.09.013.

    Article  CAS  PubMed  Google Scholar 

  55. Ip S, Chung M, Moorthy D, Yu WW, Lee J, Chan JA, et al. AHRQ comparative effectiveness reviews. Comparative effectiveness of management strategies for gastroesophageal reflux disease: update. Rockville, MD: Agency for Healthcare Research and Quality (US); 2011.

    Google Scholar 

  56. Wu MS, Tan SC, Xiong T. Indirect comparison of randomised controlled trials: comparative efficacy of dexlansoprazole vs. esomeprazole in the treatment of gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2013;38(2):190–201. https://doi.org/10.1111/apt.12349.

    Article  CAS  PubMed  Google Scholar 

  57. Shin JM, Sachs G. Pharmacology of proton pump inhibitors. Curr Gastroenterol Rep. 2008;10(6):528–34.

    Article  PubMed  PubMed Central  Google Scholar 

  58. Freedberg DE, Kim LS, Yang YX. The risks and benefits of long-term use of proton pump inhibitors: expert review and best practice advice from the American Gastroenterological Association. Gastroenterology. 2017;152(4):706–15. https://doi.org/10.1053/j.gastro.2017.01.031.

    Article  CAS  PubMed  Google Scholar 

  59. Yadlapati R, Kahrilas PJ. When is proton pump inhibitor use appropriate? BMC Med. 2017;15(1):36. https://doi.org/10.1186/s12916-017-0804-x.

    Article  PubMed  PubMed Central  Google Scholar 

  60. Yamashita H, Kanamori A, Kano C, Hashimura H, Matsumoto K, Tsujimae M, et al. The effects of switching to vonoprazan, a novel potassium-competitive acid blocker, on gastric acidity and reflux patterns in patients with erosive esophagitis refractory to proton pump inhibitors. Digestion. 2017;96(1):52–9. https://doi.org/10.1159/000478255.

    Article  CAS  PubMed  Google Scholar 

  61. Savarino E, Martinucci I, Furnari M, Romana C, Pellegatta G, Moscatelli A et al. Vonoprazan for treatment of gastroesophageal reflux: pharmacodynamic and pharmacokinetic considerations. Expert Opin Drug Metab Toxicol. 2016:1–9. doi:https://doi.org/10.1080/17425255.2016.1214714.

    Article  CAS  Google Scholar 

  62. Baldi F. PPI-refractory GERD: an intriguing, probably overestimated, phenomenon. Curr Gastroenterol Rep. 2015;17(7):451. https://doi.org/10.1007/s11894-015-0451-3.

    Article  PubMed  Google Scholar 

  63. Gunaratnam NT, Jessup TP, Inadomi J, Lascewski DP. Sub-optimal proton pump inhibitor dosing is prevalent in patients with poorly controlled gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2006;23(10):1473–7. https://doi.org/10.1111/j.1365-2036.2006.02911.x.

    Article  CAS  PubMed  Google Scholar 

  64. Fass R, Gasiorowska A. Refractory GERD: what is it? Curr Gastroenterol Rep. 2008;10(3):252–7.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Vatche and Tamar Manoukian Division of Digestive Diseases, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA

    Adarsh M. Thaker M.D. & V. Raman Muthusamy M.D., F.A.C.G., F.A.S.G.E.

Authors
  1. Adarsh M. Thaker M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. V. Raman Muthusamy M.D., F.A.C.G., F.A.S.G.E.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Adarsh M. Thaker M.D. .

Editor information

Editors and Affiliations

  1. Nebraska Medical Center, University of Nebraska Medical Center, Omaha, Nebraska, USA

    Dmitry Oleynikov

  2. Harvard Medical School, West Roxbury, Massachusetts, USA

    P. Marco Fisichella

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG, part of Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Thaker, A.M., Raman Muthusamy, V. (2018). Non-operative Treatment of Gastroesophageal Reflux Disease. In: Oleynikov, D., Fisichella, P. (eds) A Mastery Approach to Complex Esophageal Diseases. Springer, Cham. https://doi.org/10.1007/978-3-319-75795-7_1

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-75795-7_1

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-75794-0

  • Online ISBN: 978-3-319-75795-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation